Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome

European Journal of Clinical Investigation

Volumn 42, Issue 4, 2012, Pages 411-418

  Yilmaz, Yusuf ^a   Senates, Ebubekir ^b   Ayyildiz, Talat ^c   Colak, Yasar ^d   Tuncer, Ilyas ^d   Ovunc, Ayse Oya Kurdas ^b   Dolar, Enver ^c   Kalayci, Cem ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ULUDAG UNIVERSITY   (Turkey)

^d GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Fibrosis; Haemoglobin; Insulin resistance; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT TOOL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOMOESTASIS MODEL OF INSULIN RESISTANCE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TURKEY;

EID: 84858284683     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02597.x     Document Type: Article

References (34)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
3. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-50.
4. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20.
5. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
6. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-51.
7. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-49.
8. Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69.
9. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9.
10. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60(Suppl. 7):19-24.
11. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
12. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8.
13. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80.
14. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
15. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42: 32030.
16. Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-7.
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
18. Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008;9:108-12.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
21. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
22. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
23. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411:1-18.
24. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825-32.
25. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009;58:1706-7.
26. Alayash AI, Patel RP, Cashon RE. Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal 2001;3:313-27.
27. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:244-56.
28. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007;282:23698-707.
29. Pearson TC. Hemorheology in the erythrocytoses. Mt Sinai J Med 2001;68:182-91.
30. Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 2008;89:241-50.
31. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009;33:S46-57.
32. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7.
33. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
34. Alberti KG, Zimmet P, Shaw J; for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.